MENU

MDGL Stock Madrigal Pharmaceuticals (MDGL, $344.97) was a top gainer this month, soaring +21.02%. Expect an Uptrend reversal

A.I.dvisor
at Tickeron.com
Loading...
MDGL - Madrigal Pharmaceuticals
Monthly gain
Bearish Trend
Odds of DOWN Trend
Tickeron

Loading...

Price: $344.97
Daily change: +$33.83 (+10.87%)
Daily volume: 1.3M
Monthly price change: +$59.91 (+21.02%)
Capitalization: $7.7B
Industry: Biotechnology
Madrigal Pharmaceuticals (MDGL, $344.97) was one of the top gainers for the month, rising +2 to $344.97 per share. A.I.dvisor analyzed 816 stocks in the Biotechnology Industry for the month ending July 16, 2025 and discovered that of them (7) exhibited an Uptrend while of them (2) exhibited a Downtrend. A.I.dvisor found 262 similar cases when MDGL's price went up within one month. In out of those 262 cases, MDGL's price went down during the next month. Based on these historical data, A.I. thinks the odds an Uptrend reversal for MDGL are

MDGL's MACD Histogram just turned positive

The Moving Average Convergence Divergence (MACD) for MDGL turned positive on August 05, 2025. Looking at past instances where MDGL's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 05, 2025. You may want to consider a long position or call options on MDGL as a result. In of 93 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

MDGL moved above its 50-day moving average on July 31, 2025 date and that indicates a change from a downward trend to an upward trend.

The 50-day moving average for MDGL moved above the 200-day moving average on August 21, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where MDGL advanced for three days, in of 295 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 163 cases where MDGL Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 18 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 20 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MDGL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. MDGL’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.812) is normal, around the industry mean (19.994). P/E Ratio (0.000) is within average values for comparable stocks, (51.700). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.073). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (18.382) is also within normal values, averaging (325.279).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
MDGL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. MDGL showed earnings on August 05, 2025. You can read more about the earnings report here.
A.I. Advisor
published General Information

General Information

a developer of small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
200 Barr Harbor Drive
Phone
+1 267 824-2827
Employees
276
Web
http://www.madrigalpharma.com